Ceftazidime Administration Timing in Hemodialysis
No, ceftazidime should NOT be administered 1 hour before the end of hemodialysis—it must be given immediately AFTER each dialysis session is complete. 1, 2
Why Post-Dialysis Timing is Critical
Administering ceftazidime before or during dialysis results in significant drug removal and subtherapeutic plasma concentrations. The pharmacokinetic data are unequivocal:
- Approximately 50-55% of the administered ceftazidime dose is removed during a standard 4-hour hemodialysis session 3, 4
- Dialysis reduces the elimination half-life from 33.6 hours down to just 3.3 hours 3
- Dialyzer clearance of ceftazidime is approximately 55.6 mL/min, resulting in premature drug elimination 3
Giving the dose 1 hour before dialysis ends means the drug would still be actively removed during that final hour, compromising therapeutic levels. 2
Correct Dosing Protocol
The standard regimen is 1 g IV ceftazidime administered immediately after each hemodialysis session for patients on thrice-weekly dialysis schedules. 1, 2, 5
Specific Timing Recommendations:
- Administer the full dose only after the dialysis session is completely finished 1, 2
- This timing ensures the drug remains in circulation throughout the interdialytic period 2, 6
- Post-dialysis dosing achieves reliable pharmacodynamic target attainment (>70% time above MIC) for organisms with MICs ≤8 μg/mL 6, 4
Dosing for Different Interdialytic Intervals:
- 48-hour intervals: 1 g post-dialysis achieves adequate coverage 6, 4
- 72-hour intervals: Consider 2 g post-dialysis for organisms with MICs ≤8 μg/mL, or add a supplemental 500 mg dose at 48 hours if using the 1 g regimen 4, 7
Common Pitfalls to Avoid
Never reduce the individual dose size; instead extend the dosing interval if dose adjustment is needed. This preserves ceftazidime's concentration-dependent bactericidal activity. 2
Do not confuse this with vancomycin dosing, which can be given during the last hour of dialysis due to its different pharmacokinetic profile. 1 Ceftazidime requires post-dialysis administration exclusively.
For critically ill patients or resistant organisms (MIC 16-32 μg/mL), consider daily dosing of 500 mg to 1 g regardless of dialysis timing, as this may provide superior target attainment compared to post-dialysis-only dosing. 4, 5
Supporting Pharmacokinetic Evidence
The FDA label confirms that 80-90% of ceftazidime is excreted unchanged by the kidneys, with elimination occurring almost solely via glomerular filtration. 8 This renal-dependent clearance makes timing relative to dialysis absolutely critical for maintaining therapeutic drug levels.